Skip to main content
Top
Published in: Diabetologia 11/2006

01-11-2006 | Short Communication

Upregulation of adiponectin receptor 1 and 2 mRNA and protein in adipose tissue and adipocytes in insulin-resistant women with polycystic ovary syndrome

Authors: B. K. Tan, J. Chen, J. E. Digby, S. D. Keay, C. R. Kennedy, H. S. Randeva

Published in: Diabetologia | Issue 11/2006

Login to get access

Abstract

Aims/hypothesis

Polycystic ovary syndrome (PCOS) is a multifaceted metabolic disease linked with insulin resistance (IR) and obesity. Adiponectin, which is lower in IR states, exerts its glucose-lowering and anti-inflammatory effects by activating two receptors, ADIPOR1 and ADIPOR2. There are no data on the relative expression of these receptors in adipose tissue of PCOS women.

Methods

We investigated the expression of adiponectin receptors from corresponding s.c. and omental (o.m.) adipose tissue in women with PCOS compared with matched non-PCOS women. As there is a disturbance in the steroid milieu in PCOS women, we also assessed the effects of testosterone and oestradiol on adiponectin receptors using adipocytes and adipocyte explants. Real-time RT-PCR and western blotting were used to assess the relative adiponectin receptor mRNA expression and protein production, respectively. Biochemical measurements were performed in our hospital’s laboratory.

Results

We are the first to describe adiponectin receptor expression and production, in corresponding s.c. and o.m. human adipose tissues at the mRNA and protein level. We demonstrate the upregulation of mRNA expression and protein production of adiponectin receptors in women with PCOS, in s.c. and o.m. adipose tissue. Treatment of adipose tissue explants and adipocytes with testosterone and oestradiol induced the expression of adiponectin receptor mRNA and protein. There was a significant positive association between ADIPOR1/R2 expression and homeostasis model assessment, testosterone, oestradiol and triglycerides and a negative relationship with sex hormone-binding globulin.

Conclusions/interpretation

The precise reason for the upregulation of adiponectin receptors seen in PCOS women, a pro-diabetic state, is unknown, but it appears that sex steroids may play a role in their regulation in adipose tissue.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocr Rev 18:774–800PubMedCrossRef Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocr Rev 18:774–800PubMedCrossRef
2.
go back to reference Rajkhowa M, Bichnell J, Jones M et al (1994) Insulin sensitivity in women with polycystic ovary syndrome: relationship to hyperandrogenemia. Fertil Steril 61:605–612PubMed Rajkhowa M, Bichnell J, Jones M et al (1994) Insulin sensitivity in women with polycystic ovary syndrome: relationship to hyperandrogenemia. Fertil Steril 61:605–612PubMed
4.
go back to reference Yamauchi T, Kamon J, Ito Y et al (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769PubMedCrossRef Yamauchi T, Kamon J, Ito Y et al (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769PubMedCrossRef
5.
go back to reference Tan GD, Debard C, Funahashi T et al (2005) Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy. Diabetologia 48:1585–1589PubMedCrossRef Tan GD, Debard C, Funahashi T et al (2005) Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy. Diabetologia 48:1585–1589PubMedCrossRef
6.
go back to reference Legro RS (2003) Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 24:302–312PubMedCrossRef Legro RS (2003) Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 24:302–312PubMedCrossRef
7.
go back to reference Fauser B (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47CrossRef Fauser B (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47CrossRef
8.
go back to reference Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef
9.
go back to reference Fried SK, Moustaid-Moussa N (2001) Culture of adipose tissue and isolated adipocytes. Methods Mol Biol 155:197–212PubMed Fried SK, Moustaid-Moussa N (2001) Culture of adipose tissue and isolated adipocytes. Methods Mol Biol 155:197–212PubMed
10.
go back to reference Rodbell M (1964) Metabolism of isolated fat cells. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 239:375–380PubMed Rodbell M (1964) Metabolism of isolated fat cells. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 239:375–380PubMed
11.
go back to reference Chen J, Tan B, Karteris E et al (2006) Secretion of adiponectin by human placenta: differential modulation of adiponectin and its receptors by cytokines. Diabetologia 49:1292–1302PubMedCrossRef Chen J, Tan B, Karteris E et al (2006) Secretion of adiponectin by human placenta: differential modulation of adiponectin and its receptors by cytokines. Diabetologia 49:1292–1302PubMedCrossRef
12.
go back to reference Randeva HS, Karteris E, Grammatopoulos D et al (2001) Expression of orexin-A and functional orexin type 2 receptors in the human adult adrenals: implications for adrenal function and energy homeostasis. J Clin Endocrinol Metab 86:4808–4813PubMedCrossRef Randeva HS, Karteris E, Grammatopoulos D et al (2001) Expression of orexin-A and functional orexin type 2 receptors in the human adult adrenals: implications for adrenal function and energy homeostasis. J Clin Endocrinol Metab 86:4808–4813PubMedCrossRef
13.
go back to reference Quinkler M, Sinha B, Tomlinson JW et al (2004) Androgen generation in adipose tissue in women with simple obesity—a site-specific role for 17 beta-hydroxysteroid dehydrogenase type 5. J Endocrinol 183:331–342PubMedCrossRef Quinkler M, Sinha B, Tomlinson JW et al (2004) Androgen generation in adipose tissue in women with simple obesity—a site-specific role for 17 beta-hydroxysteroid dehydrogenase type 5. J Endocrinol 183:331–342PubMedCrossRef
14.
go back to reference Margolis KL, Bonds DE, Rodabough RJ et al (2004) Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial. Diabetologia 47:1175–1187PubMedCrossRef Margolis KL, Bonds DE, Rodabough RJ et al (2004) Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial. Diabetologia 47:1175–1187PubMedCrossRef
Metadata
Title
Upregulation of adiponectin receptor 1 and 2 mRNA and protein in adipose tissue and adipocytes in insulin-resistant women with polycystic ovary syndrome
Authors
B. K. Tan
J. Chen
J. E. Digby
S. D. Keay
C. R. Kennedy
H. S. Randeva
Publication date
01-11-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 11/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0419-9

Other articles of this Issue 11/2006

Diabetologia 11/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine